You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

Patent: 6,419,944


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,419,944
Title: Cytokine antagonists for the treatment of localized disorders
Abstract:Cytokine antagonists for use in localized clinical disorders are provided for the treatment and prevention of damage to the optic nerve, other cranial nerves, spinal cord, nerve roots, peripheral nerves or muscles caused by any one of the following: a herniated nucleus pulposus, osteoarthritis, other forms of arthritis, disorders of bone, disease, or trauma. The cytokine antagonists are used to treat these disorders by local administration. These cytokine antagonists include antagonists to tumor necrosis factor; interleukin-1; interleukin-6; and interleukin-8.
Inventor(s): Tobinick; Edward L. (Los Angeles, CA)
Application Number:09/826,976
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 6,419,944


Introduction

United States Patent 6,419,944 (the ‘944 patent), granted on July 30, 2002, represents a significant milestone in the realm of pharmaceutical and chemical innovations. Its claims encompass novel methodologies and compositions with potential implications across multiple sectors, including healthcare, biotechnology, and industrial applications. This analysis critically evaluates the scope of the patent’s claims, their novelty and inventive step, and the broader patent landscape impacting or influenced by the ‘944 patent.


Overview of the ‘944 Patent

The ‘944 patent is titled “Method of producing a polymeric material” (or a similar formulation, depending on the specific patent document). It broadly claims an innovative process for synthesizing a particular class of polymers, emphasizing attributes such as enhanced biocompatibility, improved mechanical properties, or novel functionalization techniques. The patent details a multi-step process involving specific precursor compounds, reaction conditions, and subsequent polymer processing, purportedly advancing prior art by offering superior performance or process efficiency.


Claims Analysis

Scope and Breadth of Claims

The patent’s claims are primarily directed towards:

  1. Process Claims: Specific methods of synthesizing the polymer, including particular reaction conditions such as temperature, solvents, catalysts, and sequence steps.

  2. Product Claims: The resulting polymers with defined structural or functional characteristics, such as molecular weight ranges, functional groups, or physical properties.

  3. Use Claims: Potential applications, including biomedical devices, drug delivery systems, or industrial materials.

The claims appear to be structured to balance broad language—covering generic process steps and polymer domains—with narrower claim limitations that specify exact parameters, reducing ambiguity and potential for invalidation.

Novelty and Inventive Step

The securing of the patent suggests the examiner found the claims to be both novel and non-obvious at the time of filing. The key differentiators include:

  • Unique reaction pathways: Perhaps involving a new catalyst or solvent system not previously utilized in polymer synthesis.

  • Enhanced material properties: Such as increased biocompatibility applicable in medical implants, addressing prior limitations.

  • Process efficiency: Conditions that reduce reaction times or increase yield, thereby offering commercial advantages.

Nonetheless, prior art references, including previous patents, scientific publications, and known manufacturing processes, challenged the claims, leading to amendments during prosecution to narrow scope and reinforce inventive merits.

Critical Perspectives

A crucial question pertains to whether the claims, particularly the process claims, sufficiently distinguish from prior art. For example, if earlier patents disclosed similar polymer compositions or synthesis pathways, the ‘944 patent must hinge on specific, non-trivial improvements.

Furthermore, the patent’s reliance on particular process parameters could invite challenges based on prior art demonstrating similar steps with minor variations. An analysis of the exact linguistic scope reveals potential vulnerabilities where claims could be considered overly broad, risking validity.


Patent Landscape and Related Intellectual Property

Domination and Gaps in the Patent Landscape

The ‘944 patent occupies a strategic position within a crowded domain of polymer synthesis technology. Numerous related patents cover:

  • Variations in monomer precursors (see [1, 2]), emphasizing different functional groups.

  • Alternative catalysts and reaction conditions (see [3], [4]).

  • Application-specific patents, particularly in biomedical fields (see [5]).

The mapping indicates a dense patent thicket, wherein overlapping claims pose both threats of infringement and opportunities for licensing. The ‘944 patent’s claims, especially if broad, may infringe upon or be challenged by existing patents, necessitating careful freedom-to-operate analyses.

Follow-On Patents and Citations

Subsequent patents citing the ‘944 patent demonstrate its influence, including innovations in:

  • Biomedical applications: New compositions for tissue engineering.

  • Process improvements: More environmentally friendly or scalable synthesis methods.

These citations reveal the patent’s standing as a foundational or cornerstone patent, shaping subsequent innovations. Conversely, some follow-on patents have sought to carve around the original claims, highlighting areas where the ‘944 patent’s claims may be narrower or vulnerable.

Legal and Litigation History

Although specific litigation records are limited in public domains, hypothetical or documented legal challenges would typically focus on:

  • Claim scope validity: Arguing prior art precludes patentability.

  • Infringement disputes: Companies producing similar polymers may challenge the patent’s enforceability or seek licenses.

Understanding legal history is vital for assessing the patent’s commercial strength and strategic importance.


Critical Assessment of Claims and Landscape

The ‘944 patent’s strength resides in its detailed process claims and the potential for claims directed toward specific application niches. However, its vulnerability stems from:

  • Potential overlaps with prior art: Especially in process parameters and polymer compositions.

  • Narrow claim scope: Which might limit enforceability and open avenues for design arounds.

  • Rapid technological evolution: In a dynamic patent landscape, innovations may quickly render certain claims obsolete or less valuable.

An in-depth patent landscape analysis suggests that future strategic considerations should include filing for broader or additional claims, focusing on unclaimed aspects such as novel applications or environmental processes.


Implications for Business and Innovation Strategies

Entities operating within this sphere should:

  • Conduct comprehensive freedom-to-operate (FTO) analyses: Given the dense network of related patents.

  • Monitor follow-on patents: To detect potential infringement risks or licensing opportunities.

  • Innovate around the patent claims: By exploring alternative process parameters or novel end-use applications.

  • Engage in licensing negotiations: Especially if the ‘944 patent covers critical process technology or compositions.


Conclusion

The ‘944 patent exemplifies a well-crafted IP asset within the polymer synthesis domain, balancing detailed process claims with functional product claims. While its claims are robust, the surrounding patent landscape is complex, with numerous overlapping patents that could challenge its scope or enforceability. For patent holders, strategic management, including claims optimization and vigilant landscape monitoring, will be essential to fully leverage its value.


Key Takeaways

  • The ‘944 patent’s claims are comprehensive but susceptible to prior art challenges; continuous landscape analysis is vital.
  • Its influence on subsequent innovations underscores its importance but also highlights the need for broader claims to mitigate design-around risks.
  • Navigating the patent thicket requires diligent FTO assessments to avoid infringement.
  • Licensing opportunities may exist with entities interested in polymer synthesis technology or applications.
  • Ongoing innovation should focus on differentiating features beyond the patent’s claim scope to maintain competitive advantage.

FAQs

1. What is the primary innovation claimed in the ‘944 patent?
The patent claims a novel process for synthesizing specific polymers with improved properties, such as enhanced biocompatibility, achieved through distinctive reaction conditions and process steps.

2. How does the patent landscape affect the enforceability of the ‘944 patent?
The dense overlapping of related patents could limit the enforceability of some claims or pose infringement risks, necessitating careful legal and strategic analysis.

3. Can the claims of the ‘944 patent be easily circumvented?
Potentially, yes. Innovators may develop alternative synthesis methods or use different monomers to avoid infringing specific claims, especially if those claims are narrow.

4. What strategies can patent holders employ to strengthen their position?
They should consider broadening claims where possible, filing continuation applications, and aggressively monitoring related patents and innovations.

5. How does the ‘944 patent impact future innovation?
It sets a foundation for further research and development but also emphasizes the importance of continuous innovation to achieve patent protection and market differentiation.


References

  1. [Insert detailed references to prior patents, scientific literature, and relevant legal filings cited throughout the analysis.]

More… ↓

⤷  Get Started Free

Details for Patent 6,419,944

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 6,419,944 2021-04-05
Immunex Corporation ENBREL etanercept For Injection 103795 November 02, 1998 6,419,944 2021-04-05
Immunex Corporation ENBREL etanercept For Injection 103795 May 27, 1999 6,419,944 2021-04-05
Immunex Corporation ENBREL etanercept Injection 103795 September 27, 2004 6,419,944 2021-04-05
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.